Drug Profile
Levosalbutamol - Sumitomo Pharma America
Alternative Names: Levalbuterol; R-albuterol; R-salbutamol; Xopenex; Xopenex HFA; Xopenex MDI®Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sepracor
- Developer Sepracor; Sumitomo Pharma America
- Class Antiasthmatics; Benzene derivatives; Bronchodilators; Ethanolamines; Phenethylamines; Skin disorder therapies; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
- Discontinued Acute asthma
Most Recent Events
- 09 Jul 2019 No recent reports on development identified - Phase-III for Asthma (In children, In infants, In neonates) in USA (Inhalation, Aerosol)
- 09 Jul 2019 No recent reports on development identified - Phase-III for Asthma (In children, In infants, In neonates) in USA (Inhalation, Liquid)
- 21 May 2015 Sunovion terminates phase III trial in Asthma in USA (NCT02150499)